Testing VIM0423 for tremor in adults with Parkinson's disease
Tests VIM0423 for tremor in adults whose Parkinson's disease medicines help too little.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Key facts
- Where
- Albuquerque, Altamonte Springs, Amherst, Arlington, Atlanta, Aventura, Baltimore, Canton, Cypress, Dallas, Decatur, Farmington Hills, Kirkland, Memphis, Miami, Murrieta, Naples, New York, Olney, Overland Park, Palm Beach, Patchogue, Raleigh, Round Rock, Scottsdale, Spokane, Stamford, and Tampa, United StatesSee the 29 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07804615, who can take part
Where in United States
- AlbuquerqueAlbuquerque, United StatesNot yet recruiting
- Altamonte SpringsAltamonte Springs, United StatesNot yet recruiting
- AmherstAmherst, United StatesNot yet recruiting
- ArlingtonArlington, United StatesNot yet recruiting
- AtlantaAtlanta, United StatesNot yet recruiting
- AventuraAventura, United StatesNot yet recruiting
- BaltimoreBaltimore, United StatesNot yet recruiting
- CantonCanton, United StatesNot yet recruiting
- CypressCypress, United StatesNot yet recruiting
- DallasDallas, United StatesNot yet recruiting
- DecaturDecatur, United StatesTaking people
- Farmington HillsFarmington Hills, United StatesTaking people
- KirklandKirkland, United StatesNot yet recruiting
- MemphisMemphis, United StatesTaking people
- MiamiMiami, United StatesNot yet recruiting
- MurrietaMurrieta, United StatesTaking people
- NaplesNaples, United StatesNot yet recruiting
- New YorkNew York, United StatesNot yet recruiting
- OlneyOlney, United StatesNot yet recruiting
- Overland ParkOverland Park, United StatesNot yet recruiting
- Palm BeachPalm Beach, United StatesNot yet recruiting
- PatchoguePatchogue, United StatesNot yet recruiting
- RaleighRaleigh, United StatesNot yet recruiting
- Round RockRound Rock, United StatesNot yet recruiting
- ScottsdaleScottsdale, United StatesNot yet recruiting
- ScottsdaleScottsdale, United StatesNot yet recruiting
- SpokaneSpokane, United StatesNot yet recruiting
- StamfordStamford, United StatesNot yet recruiting
- TampaTampa, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vima Therapeutics
- Trial code
- NCT07804615
- Record updated
- 10 November 2026
- Original description
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.Read full original descriptionShow less
A Phase 2 Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
The main objectives of this clinical trial are to determine the following:
* Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease? * Is VIM0423 well tolerated in individuals with Parkinsons's disease? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Inclusion: Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening); Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015 criteria which must include tremor as one of the cardinal characteristics; Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1 (Screening); with no anticipated changes to said therapies for the duration of the study; and on a minimum of 300 mg LEDD. Cohort 2: Individuals who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study; The participants must meet protocol-specified requirements for baseline tremor scores.
Exclusion: Currently (within 7 days of Screening) taking any anticholinergic medication; Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided focused ultrasound thalamotomy, ablative thalamotomy, gamma knife thalamotomy); Other protocol-specified inclusion and exclusion criteria may apply.